Compare HRMY & CLVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HRMY | CLVT |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | 12000 |
| Industry | Biotechnology: Pharmaceutical Preparations | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.6B | 1.7B |
| IPO Year | 2020 | N/A |
| Metric | HRMY | CLVT |
|---|---|---|
| Price | $32.44 | $2.84 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 9 | 7 |
| Target Price | ★ $44.11 | $3.22 |
| AVG Volume (30 Days) | 799.5K | ★ 5.2M |
| Earning Date | 05-07-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 7.97 | N/A |
| EPS | ★ 2.71 | N/A |
| Revenue | ★ $868,453,000.00 | N/A |
| Revenue This Year | $19.75 | N/A |
| Revenue Next Year | $12.88 | $2.12 |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | ★ 21.51 | N/A |
| 52 Week Low | $25.52 | $1.66 |
| 52 Week High | $40.87 | $4.77 |
| Indicator | HRMY | CLVT |
|---|---|---|
| Relative Strength Index (RSI) | 66.25 | 60.97 |
| Support Level | $32.13 | $2.29 |
| Resistance Level | $33.21 | $3.73 |
| Average True Range (ATR) | 1.32 | 0.20 |
| MACD | 0.19 | 0.03 |
| Stochastic Oscillator | 58.88 | 68.66 |
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
Clarivate is a data, information, and software workflow solutions company serving customers primarily in academia, government, law, life sciences, and healthcare. The company was formerly part of Thomson Reuters before being sold to private equity as an independent company in 2016. In 2019, Clarivate went public on the New York Stock Exchange. Around half of the company's revenue is generated in the Americas, while Europe, Middle East, and Africa account for around a quarter.